Adaptive clinical trials in tuberculosis: applications, challenges and solutions

Area of Science:

• Clinical trial methodology
• Tuberculosis drug development
• Regulatory science

Background:

• Tuberculosis (TB) drug development faces significant hurdles, including complex combination therapies, limitations of animal models, and the absence of validated surrogate endpoints for cure.
• Large, lengthy, and expensive Phase III trials are a bottleneck, with limited global funding and capacity, necessitating more efficient methods for selecting promising drug regimens.
• Multidrug-resistant TB presents unique challenges due to limited patient numbers and trial complexity.

Purpose of the Study:

• To evaluate the suitability of adaptive clinical trial designs for tuberculosis drug development.
• To identify how adaptive designs can enhance efficiency in Phase IIB and Phase III trials for TB.
• To explore the potential of adaptive designs in optimizing drug dose and combination selection and strengthening confirmatory trials.

Main Methods:

• Examination of adaptive clinical trial designs.
• Focus on application in Phase IIB and Phase III trials for tuberculosis.
• Analysis of potential benefits for dose-finding, combination selection, and confirmatory efficacy studies.

Main Results:

• Adaptive designs offer potential for improved efficiency in early-phase (Phase IIB) drug development for TB.
• These designs can enhance the power and feasibility of late-phase (Phase III) confirmatory trials, particularly for multidrug-resistant TB.
• Adaptive approaches can streamline the selection of optimal drug doses and combinations.

Conclusions:

• Adaptive clinical trial designs present a promising strategy to overcome practical obstacles in tuberculosis drug development.
• Adoption of these designs by trialists and regulators could lead to more effective and rapid identification of superior TB treatment regimens.
• This approach holds the potential to accelerate global efforts to combat tuberculosis.